Reports Q4 revenue $98.3M, consensus $88.66M. "We added 59 new programs to the cell programming platform in 2022 as our team delivered toward the high end of our program guidance," said Jason Kelly, co-founder and CEO of Ginkgo. "This outstanding performance illustrates strong growth in customer demand as our capabilities progress. Each new program is valuable to Ginkgo, expanding and scaling our platform capabilities and driving financial value. Importantly, we continue to see great sales momentum with biopharma customers, who represent both the most sophisticated and largest end market opportunity for us today. Our long-term Biosecurity strategy is also developing nicely as we build a strong base of more recurring biosecurity revenue through our biosurveillance and international partnerships on top of any potential continued COVID-19 testing. I’m very excited about Ginkgo’s ability to drive growth and platform improvements in 2023, and our cash balance of over $1.3 billion provides us significant flexibility in an uncertain macroeconomic environment."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on DNA:
- Ginkgo Bioworks Reports Fourth Quarter and Full Year 2022 Financial Results
- Ginkgo Bioworks options imply 10.1% move in share price post-earnings
- Ginkgo Bioworks, Zymtronix announce partnership
- Ginkgo Bioworks to lead pathogen monitoring program at Kigali Airport, Rwanda
- Cathie Wood Gets Back on Track; Here Are 2 Stocks She’s Snapping Up